Sle clinical trials

Explore recruiting sle clinical trials.

Recruiting sle studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Sle trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)

France, Spain, Portugal, Germany, Belgium, Poland +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

The effects of rituximab and obinutuzumab on lymphocyte subsets in peripheral blood and lymphoid tissues of SLE patients

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

(Synbiose-2 )Synergetic B-cell immunomodulation in SLE – 2 nd study

Netherlands

Phase II and Phase III (Integrated) EU CTIS Study details

A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3667 in adult subjects with active systemic lupus erythematosus.

Germany, France, Spain, Poland, Bulgaria, Hungary

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Afimetoran in Participants with Active Systemic Lupus Erythematosus.

Romania, Ireland, Spain, Germany, France, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2)

Hungary, Czechia, Portugal, Spain, Poland, Bulgaria +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Sle trials by city

Sle in Toronto Sle in Vancouver Sle in Montreal Sle in Calgary Sle in Edmonton Sle in Ottawa Sle in Winnipeg Sle in Quebec City Sle in Hamilton Sle in Kitchener Sle in London Sle in Halifax Sle in New York Sle in Los Angeles Sle in Chicago Sle in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease